CVI Holdings’s Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share DNA.WS Stock Holding History

CVI Holdings’s Portfolio DNA.WS Stock Details DNA.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-413,527	Closed	-$93K	–	227
2023 Q3	$93K	Sell	413,527 -371,350	-47%	-$99.7K	0.18%	43
2023 Q2	$206K	Sell	784,877 -437,716	-36%	-$85.3K	0.22%	54
2023 Q1	$220K	Sell	1,222,593 -233,585	-16%	-$53.5K	0.08%	137
2022 Q4	$291K	Sell	1,456,178 -381,528	-21%	-$164K	0.04%	255
2022 Q3	$1.32M	Sell	1,837,706 -89,115	-5%	-$60.9K	0.1%	293
2022 Q2	$1.02M	Hold	1,926,821	–	–	0.07%	349
2022 Q1	$1.7M	Sell	1,926,821 -326,185	-14%	-$363K	0.11%	300
2021 Q4	$5.05M	Buy	2,253,006 +756,783	+51%	+$2.45M	0.33%	66
2021 Q3	$5.07M	Buy	+1,496,223	New	+$5.33M	0.32%	77

Other funds holding DNA.WS

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

JRCM

Jones Road Capital Management New York $55.3M AUM 29.97% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

CVI Holdings's DNA.WS Position: Q4 2023 in Review

CVI Holdings sold out of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) in Q4 2023, closing a stake of 413,527 shares — an estimated $93K sold.

CVI Holdings first reported a position in DNA.WS in Q3 2021 and held it in 9 quarters. The position peaked at $5.07M in Q3 2021. 34 funds tracked by Wall St. Rank hold DNA.WS as of Q4 2023.

CVI Holdings reported no remaining Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position as of Q4 2023 after selling out during the quarter.
CVI Holdings sold 413,527 Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share shares in Q4 2023, an estimated $93K.
CVI Holdings first reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in Q3 2021 and held it in 9 quarters.
CVI Holdings's Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share position peaked at $5.07M in Q3 2021.
34 funds tracked by Wall St. Rank held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share as of Q4 2023.

Based on CVI Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.